Day: August 20, 2025

TORONTO, Ontario, Aug. 19, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company“) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that it has entered into a memorandum of understanding with Hartree Partners, LP (“Hartree“) and funds managed by Oaktree Capital Management, L.P. (“Oaktree“, together with Hartree, the “Lenders“, and each a “Lender“) which consists of a previously agreed to bridge loan (the “Bridge Loan“) with Nussir ASA, a 93.55% owned subsidiary of the Company, as borrower, and Keystone Mines Inc., Blue Moon Norway AS and Repparfjord Eiendom AS, each a wholly owned subsidiary of the Company, as guarantors, as well as terms related a project financing package (the “Project Finance Package” and together...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Aug. 19, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) announces the resignation of Mr. Mike Maguire as Chief Executive officer and the appointment of Mr. Lonn Bate as Interim Chief Executive Officer, effective today, August 19, 2025. Mr. Bate has been Chief Financial Officer of the Corporation since July 1, 2024 and prior to that he has been involved with the Corporation in a consulting capacity from March 2023. In addition, the Corporation is pleased to announce the appointment of Mr. Jay Bachman as Interim Chief Financial Officer, also effective August 19, 2025, subject...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) as a first-line treatment in certain non-small cell lung cancer (“NSCLC”) patients whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression. The last patient was enrolled on August 18, 2025. This Phase III trial is a blinded, randomized, controlled study in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression. The study will evaluate the efficacy and safety of TAGRISSO® in combination with ORPATHYS® comparing to TAGRISSO® alone, a standard-of-care...